AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01140672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.
Study NCT01140672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.
Study NCT04276818 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP group
Description: Demonstrating the effectiveness of dressing with PRP in the treatment of second-degree burns
Study NCT04276818 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment group
Description: The effectiveness of conventional dressing containing silver sulfadiazine in the treatment of burns will be compared with the method of dressing with PRP.
Study NCT03753971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound stimulation
Description: Short sound stimulations will be emitted through a head band during sleep apneas
Study NCT00113698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Up-titration period is to reach the highest tolerated dose up to a maximum of 0.4 mg/kg/day
Study NCT00113698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo An inert preparation with similar appearance and taste to the drug
Study NCT00026637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: Sertraline: 25-200mg PO (orally); Subjects begin at 25mg for week 1 and increase to 50mg at the beginning of week 2. Sertraline is increased in 50mg increments when subjects score in the depressed range on the CES-D, a questionnaire that is administered every 2 weeks over the 16 week intervention period. Subjects may reduce dosage if toxicity occurs.
Study NCT00026637 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavior therapy
Description: CBT (Cognitive Behavior Therapy) - CBT is a psychotherapy based on modifying cognitions, assumptions, beliefs and behaviors, with the aim of influencing disturbed emotions. Subjects will meet with a trained CBT therapist for 1 hour each week over the 16 week intervention period and will be given assignments to work on each week.
Study NCT00507026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Diclofenac
Description: IV Diclofenac q6h
Study NCT00507026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ketorolac
Description: IV ketorolac q6h
Study NCT00507026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo q6h
Study NCT05345912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-745 IV Solution
Description: CG-745 IV: Supplied as 125 mg/vial Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
Study NCT05345912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-750 125mg capsule
Description: CG-750 capsule: Supplied as 125 mg/capsule Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
Study NCT05345912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PO Placebo
Description: PO Placebo: Supplied as placebo capsule (same appearance as in CG-750 Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
Study NCT03043365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCMUFA-rich saury oil
Description: 4 capsules, 3 times a day after meals
Study NCT03987399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored educational intervention
Description: Educational day (lecture and workshop), clinical supervision and reminders
Study NCT02830373 — intervention group
Intervention type: DEVICE
Intervention: LVIS stents
Description: Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
Study NCT00095121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLB)
Description: Matching placebo
Study NCT00095121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir Dipivoxil (ADV)
Description: 10-mg tablet or 2-mg/mL oral suspension
Study NCT00095121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration >= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained >= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.
Study NCT00095121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lamivudine
Description: 100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration >= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained >= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.
Study NCT03199092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RRT+sat
Description: RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. For this study, RRT was delivered in combination with a specific auditory training involving several music games specifically designed for improving auditory processing abilities typically compromised in children with DD.
Study NCT03199092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abilmente
Description: 'Abilmente' method is an intervention for DD that comprises several validated treatments resulting in a proposal tailored to meet individual needs and features.
Study NCT02207192 — intervention group
Intervention type: OTHER
Intervention: Postural change in lung volumes: sitting to Supine
Description: Pulmonary function and arterial blood gases were assessed both prior to and after weight loss as part of pre-operative and 12-month follow-up evaluations.~Pulmonary function tests were performed both in the sitting and then in the supine position.
Study NCT00756977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI850
Description: multi-dose preparation for oral administration prior to colonoscopy
Study NCT00756977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol 3350 based bowel preparation
Description: multi-dose preparation for oral administration prior to colonoscopy
Study NCT02636790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery wait time
Description: VCH CRS patients need a waitlist system that promotes wellness and ensures care that focuses on quality - this can be achieved with a prioritized waitlist based on quality of life improvement and decreased healthcare expenditure.
Study NCT06096194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D-enhanced egg
Description: In our study, the vitamin D3-enhanced eggs were produced by hens that received 23,500 IU of vitamin D3 per kg of feed. Which does not confer them any harm or danger of intoxication. This experiment was carried out at the Center for Teaching, Research and Extension in Poultry Production (CEIEPAv, FMVZ-UNAM) and lasted 40 weeks.~This ensured that the hens eggs were enhanced with vitamin D achieving a final concentration of approximately 400 IU of vitamin D
Study NCT06096194 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Unfortified eggs were used for the control group with a concentration of approximately 43 IU of vitamin D
Study NCT02746679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: Mindfulness Based Stress Reduction programs have been shown to be effective, however, the potential benefits of Mindfulness Based Stress Reduction to decrease depression, anxiety, stress in other diseases. Therefore, the purpose of this study was to examine whether MBSR is effective, and has potential as an intervention to decrease depression, anxiety ,and to improve quality of life of intrauterine adhesion patients.
Study NCT05345912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV Placebo: 0.9 % normal saline
Description: IV Placebo: 0.9 % normal saline Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
Study NCT04454762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: oral administration (40 mg daily, reduced dose 20 mg daily)
Study NCT01855880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Study NCT01855880 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02174185 — intervention group
Intervention type: BEHAVIORAL
Intervention: validated health-related quality of life questionnaires
Description: All eligible patients who agree to participate will be asked to fulfill three different validated health-related quality of life questionnaires (EORTC-QLQ-C30/BLM, FACT-BL and BCI) prior to surgery and at 3, 6, 12, 18 months postoperatively.
Study NCT04085861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental health literacy in dancers
Description: Receive a designed informative intervention (3 workshops of 90min each) aimed at improving their knowledge and skills on proper recovery, performance nutrition, and mental health literacy.
Study NCT04085861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental health literacy in dance teachers
Description: Receive a designed informative intervention (3 workshops of 60min each) aimed at improving their knowledge and skills on how to identify and deal with mental health- and nutritional issues in dancers.
Study NCT01127087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxazyme
Description: Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily.
Study NCT00580229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: prednisone 40mg by mouth 30-60 minutes prior to rituximab
Study NCT02498743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: echocardiography
Description: TV was connected to display the cartoon video during the echocardiography: the episode number 125 of 'Dora the Explorer': 'Baby Winky Goes Home!' was reproduced during the echocardiography.
Study NCT02498743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watching Animated cartoons
Study NCT04640987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Prodigy System
Description: Device used for production of T-allo10 cells.
Study NCT00673634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard preoxygenation
Description: Spontaneous breathing of 100% oxygen in a facemask for 3 minutes.
Study NCT00673634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP assisted preoxygenation
Description: Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4cm H2O and a positive end-expiratory pressure of 4cm H2O, for 3 minutes.
Study NCT02838225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Doxorubicin
Study NCT02838225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, Doxorubicin, Cyclophosphamide
Study NCT02826564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Study NCT03587987 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neopff
Description: manual ventilation
Study NCT02427919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Comparison of the effect of G-CSF use
Study NCT02427919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Comparison of the effect of G-CSF use
Study NCT02940613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual feedback of symptom frequency
Description: Participants receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
Study NCT03587987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rPap
Description: Manual ventilation
Study NCT00219141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 150/300 mg
Description: Aliskiren 150 mg tablets
Study NCT00219141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50/100 mg
Description: Losartan 50 or 100 mg capsules
Study NCT02924025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: Motivational interview is an interview form based on the patients own thoughts of motivation. It will be conducted by a nurse who is specially trained in this interview type.
Study NCT03578497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist Anakinra
Description: IL-1 receptor antagonist Anakinra is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Standard dosage licensed by the FDA and European Medicines Agency (EMA) is 100 mg Anakinra daily. It is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colourless-to-white, preservative free solution for daily s.c. administration.
Study NCT04372641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: p97 Inhibitor CB-5339 Tosylate
Description: Given PO
Study NCT00219141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50/100 mg
Description: Losartan 50 or 100 mg capsules
Study NCT00219141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren placebo
Description: Aliskiren 150 mg placebo tablet
Study NCT04080076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Tab Tacrolimus
Description: Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 2 X week
Study NCT00914303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3241
Description: Oral Tablet, Repeated Administration
Study NCT00914303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablet
Description: Oral Tablet. Repeated Administration
Study NCT00755911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tissue Repair Cells (TRC)
Description: 30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
Study NCT04640987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-allo10 cells addback
Description: T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.
Study NCT03612895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internal Care Coordination
Description: This individual will primarily initiate, guide, and optimize adherence to the care that others deliver, rather than providing direct care his or herself. S/he will call the smoker to conduct a brief assessment of tobacco use and readiness to quit, offer brief counseling and motivational intervention, describe the available pharmacologic and behavioral options, help the smoker to choose among them, and link the smoker to chosen resources. The resources offered will include both internal (health care system based) and external (community based) tobacco cessation resources.
Study NCT03612895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Community Referral
Description: Massachusetts (MA) Helpline services include an assessment of smoking history and readiness to quit, advice to quit, self-help materials and telephone counseling. For smokers who set a quit date in the next 30 days, the Helpline offers up to 5 proactive telephone counseling calls with options for text messaging and web-based resources. It also provides eligible smokers 4 weeks of free nicotine patch or gum mailed to their home.
Study NCT00219141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren placebo
Description: Aliskiren 150 mg placebo tablet
Study NCT00219141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50/100 mg placebo
Description: Losartan 50/100 mg placebo capsules
Study NCT02053779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.1mg
Description: Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.
Study NCT03055832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLux 2020 System
Description: Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
Study NCT03055832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow Pulsation System
Description: Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
Study NCT02724787 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Manage Emotions to Reduce Aggression (MERA)
Description: MERA is a 3-session group treatment that teaches Veterans the purpose of emotions, how trauma and combat can increase emotions, and how to better regulate them. The skills use cognitive-behavioral and mindfulness techniques to help Veteran better regulate their emotions. These skills are commonly used in clinical practice, but have not been delivered in 3 sessions.
Study NCT05307900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Confirmation of feeding tube placement in critically ill patients
Description: Confirmation of feeding tube placement using ultrasonography
Study NCT01585922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: noninvasive positive pressure ventilation (NPPV)
Description: Use NPPV to treat the ARDS patients,and we choose the NPPV ventilators in which the FiO2 can be fixed, for example: the BiPAP Vision or V60 of Phillip Respironics.
Study NCT01585922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: invasive mechanical ventilation
Description: Intubate and give invasive mechanical ventilation to the other group patients when they are allocated at once.
Study NCT03108287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAK therapy
Description: rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg twice-daily
Study NCT03108287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBAK therapy
Description: rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg, bismuth subcitrate 360mg twice-daily
Study NCT00988962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral training
Description: electronic diaries, compliance checklists, urine screens, individual and group motivational counseling
Study NCT00755911 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
Study NCT01980979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remodulin
Description: Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
Study NCT03508128 — intervention group
Intervention type: OTHER
Intervention: surgical procedure
Description: Surgical procedure
Study NCT00755911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control
Description: Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
Study NCT04132375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INM004
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses.